EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High‐Affinity Superantigen‐Based Trifunctional Immune Cell Engager Synergizes NK and T Cell Activation for Tumor Suppression

Yao-An Yu, Wan-Ju Lien, Wen-Ching Lin, Yi-Chung Pan, Sin-Wei Huang, Chung-Yuan Mou, Che-Ming Jack Hu iD, Kurt Yun Mou

Advanced Science · 2024

DOI: 10.1002/advs.202310204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yao-An Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan. Hauptthemen laut MEDLINE: Killer Cells, Natural, T-Lymphocytes, Superantigens. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Confocal Microscopy Core, DNA Sequencing Core, Inflammation Core Facility.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of immune cell engagers (ICEs) can be limited by logistical and functional restrictions associated with fusion protein designs, thus limiting immune cell recruitment to solid tumors. Herein, a high affinity superantigen‐based multivalent ICE is developed for simultaneous activation and recruitment of NK and T cells for tumor treatment. Yeast library‐based directed evolution is adopted to identify superantigen variants possessing enhanced binding affinity to immunoreceptors expressed on human T cells and NK cells. High‐affinity superantigens exhibiting improved immune‐stimulatory activities are then incorporated into a superantigen‐based tri‐functional yeast‐display‐enhanced multivalent immune cell engager (STYMIE), which is functionalized with a nanobody, a Neo‐2/15 cytokine, and an Fc domain for tumor targeting, immune stimulation, and prolonged circulation, respectively. Intravenous administration of STYMIE enhances NK and T cell recruitment into solid tumors, leading to enhanced inhibition in multiple tumor models. The study offers design principles for multifunctional ICEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalT-LymphocytesSuperantigensMiceAnimalsHumansLymphocyte ActivationNeoplasmsDisease Models, AnimalImmunotherapyCell Line, Tumor

Stichwörter der Autor:innen

cancer Immunotherapydirected evolutionfusion proteinimmune cell engagersuperantigens

Substanzen

Superantigens

Autor:innen und Institutionen

  • Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan.
  • Doctoral Degree Program of Translational Medicine, National Yang Ming Chiao Tung University and Academia Sinica, Taipei, 112, Taiwan.
  • Department of Chemistry, National Taiwan University, Taipei, 10617, Taiwan.
  • Biomedical Translation Research Center, Academia Sinica, Taipei, 11529, Taiwan.

ORCID-Profile: Che-Ming Jack Hu

Förderung

  • Confocal Microscopy Core
  • DNA Sequencing Core
  • Inflammation Core Facility
  • Institute of Biomedical Sciences
  • National Science and Technology Council

Zitieren

APA

Yu, Y. A., Lien, W. J., Lin, W. C., Pan, Y. C., Huang, S. W., Mou, C. Y., Hu, C. J., & Mou, K. Y. (2024). High‐Affinity Superantigen‐Based Trifunctional Immune Cell Engager Synergizes NK and T Cell Activation for Tumor Suppression. Advanced Science. https://doi.org/10.1002/advs.202310204

Vancouver

Yu YA, Lien WJ, Lin WC, Pan YC, Huang SW, Mou CY, et al. High‐Affinity Superantigen‐Based Trifunctional Immune Cell Engager Synergizes NK and T Cell Activation for Tumor Suppression. Advanced Science. 2024. doi:10.1002/advs.202310204

BibTeX
@article{Yu2024,
  author = {Yu, Yao-An and Lien, Wan-Ju and Lin, Wen-Ching and Pan, Yi-Chung and Huang, Sin-Wei and Mou, Chung-Yuan and Hu, Che-Ming Jack and Mou, Kurt Yun},
  title = {High‐Affinity Superantigen‐Based Trifunctional Immune Cell Engager Synergizes NK and T Cell Activation for Tumor Suppression},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202310204}
}
Kostenlos starten →